Tiziana Life Sciences (NASDAQ:TLSA) Upgraded at Zacks Research

Zacks Research upgraded shares of Tiziana Life Sciences (NASDAQ:TLSA) to a hold rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other analysts have also recently issued reports on the company. Wall Street Zen cut Tiziana Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, April 18th. Weiss Ratings lowered Tiziana Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 29th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Tiziana Life Sciences currently has an average rating of “Reduce”.

Tiziana Life Sciences Trading Down 0.9%

NASDAQ:TLSA opened at $1.10 on Tuesday. The company has a fifty day moving average of $1.29 and a 200 day moving average of $1.35. Tiziana Life Sciences has a 52 week low of $1.04 and a 52 week high of $2.60.

Tiziana Life Sciences (NASDAQ:TLSA) last announced its quarterly earnings results on Friday, May 1st. The company reported ($0.28) earnings per share (EPS) for the quarter. On average, sell-side analysts predict that Tiziana Life Sciences will post -0.16 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Bison Wealth LLC bought a new stake in shares of Tiziana Life Sciences during the 4th quarter valued at about $30,000. Zhang Financial LLC increased its position in shares of Tiziana Life Sciences by 18.6% during the fourth quarter. Zhang Financial LLC now owns 99,900 shares of the company’s stock valued at $149,000 after buying an additional 15,700 shares during the period. Rachor Investment Advisory Services LLC bought a new position in Tiziana Life Sciences in the fourth quarter worth about $25,000. OMERS ADMINISTRATION Corp bought a new position in Tiziana Life Sciences in the fourth quarter worth about $59,000. Finally, Marshall Wace LLP raised its stake in Tiziana Life Sciences by 5.2% in the fourth quarter. Marshall Wace LLP now owns 282,017 shares of the company’s stock worth $420,000 after buying an additional 14,005 shares in the last quarter.

About Tiziana Life Sciences

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.